Physician profile
Duncan Friedman
NPI 1457512725
$8,756.32
in general payments reported to CMS, 2019-2025
29 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 83% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,919 · 2020: $20.37 · 2021: $753 · 2022: $1,116 · 2023: $1,558 · 2024: $1,415 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,947.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,659.56 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $1,545.27 | 2021-2025 | Vabysmo, Susvimo, Lucentis |
| Regeneron Healthcare Solutions, INC. | $976.24 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $572.53 | 2022-2025 | |
| Astellas Pharma US INC | $528.09 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $413.81 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $316.98 | 2021-2024 | Eylea, Eylea Hd |
| Notal Vision, INC. | $312.11 | 2022 | |
| Alcon Vision LLC | $277.62 | 2023-2025 | Centurion, Clareon, Rocklatan |
| Harrow Eye, LLC | $224.25 | 2025 | Triesence, Iheezo |
| Allergan, INC. | $161.60 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $144.44 | 2019-2021 | |
| Dutch Ophthalmic, USA | $143.26 | 2024 | Tissueblue, Eva, Combined Machine |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | Syfovre |
| Mallinckrodt Enterprises LLC | $122.08 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Optovue, INC. | $120.14 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $116.86 | 2022 | |
| Genentech, INC. | $108.54 | 2025 | Vabysmo |
| Horizon Therapeutics Plc | $108.39 | 2023 | Tepezza |
| Nova Eye, INC. | $105.13 | 2025 | |
| Rxsight INC | $101.10 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Biogen, INC. | $92.60 | 2022 | |
| Eyepoint US, INC. | $74.45 | 2021 | |
| Mallinckrodt Hospital Products INC. | $59.69 | 2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $45.66 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $44.48 | 2023 | Cequa |
| Bausch & Lomb Americas INC. | $34.60 | 2024 | Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duncan Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.